SPHRY News Alert Starpharma Hldgs ADR (SPHRY) 3.7600 02/15/2015
Post# of 64074
Posted On: 02/15/2015 2:53:55 PM
Starpharma Hldgs ADR (SPHRY) 3.7600 $SPHRY
Starpharma Holdings Limited CEO Dr. Jackie Fairley to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live" on February 14, 2015
Marketwired - Fri Feb 13, 6:15AM CST
Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY), a company that researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and agrochemical applications announced today that Chief Executive Officer (CEO), Dr. Jackie Fairley will be interviewed live on iHeart Radio's Health Tech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Dr. Fairley will discuss VivaGel(R), the company's development of the world's first antiviral condom (the VivaGel(R) condom) which was recently launched in Australia by Starpharma's partner, Ansell. Dr Fairley will also talk about Starpharma's current US Phase III clinical trials of VivaGel(R) for the prevention of recurrent bacterial Vaginosis as well as its development of the clinical trial of the company's improved version of cancer drug docetaxel (Taxotere). The Company's product, DEP(TM) docetaxel is a dendrimer-enhanced nanoparticle formulation which is currently in a Phase I clinical trial in cancer patients. DEP(TM) docetaxel has shown a number of benefits compared to the commercial version of docetaxel, Taxotere(R) and this platform delivery technology can be used to improve other pharmaceuticals as well. Starpharma also applies its proprietary dendrimers to improve the performance of agrochemical products such as glyphosate (the active ingredient in Roundup(R)) and has a series of partnerships with leading industry players. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
ANN: 36.52 (+0.52)
Starpharma: VivaGel(R) Condom Receives TGA Device Certification - Launch Preparations to Follow
Business Wire - Sun Jul 20, 10:05PM CDT
Starpharma (ASX:SPL) (OTCQX:SPHRY) today announced achievement of a major milestone with the receipt of Conformity Assessment Certification for the VivaGel(R) condom by the Australian Therapeutic Goods Administration (TGA). This TGA certification is similar to CE certification of devices (CE Mark) in Europe.
ANN: 36.52 (+0.52)
FDA Grants Special Protocol Assessment (SPA) Agreement for Starpharma Phase 3 Recurrent BV Trial
Business Wire - Mon Jul 14, 4:35AM CDT
Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) today announced that the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel(R) bacterial vaginosis (BV) product for the prevention of recurrent BV.
Starpharma Holdings Limited CEO Dr. Jackie Fairley to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM's "Health Tech Talk Live" on February 14, 2015
Marketwired - Fri Feb 13, 6:15AM CST
Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY), a company that researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and agrochemical applications announced today that Chief Executive Officer (CEO), Dr. Jackie Fairley will be interviewed live on iHeart Radio's Health Tech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios - 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Dr. Fairley will discuss VivaGel(R), the company's development of the world's first antiviral condom (the VivaGel(R) condom) which was recently launched in Australia by Starpharma's partner, Ansell. Dr Fairley will also talk about Starpharma's current US Phase III clinical trials of VivaGel(R) for the prevention of recurrent bacterial Vaginosis as well as its development of the clinical trial of the company's improved version of cancer drug docetaxel (Taxotere). The Company's product, DEP(TM) docetaxel is a dendrimer-enhanced nanoparticle formulation which is currently in a Phase I clinical trial in cancer patients. DEP(TM) docetaxel has shown a number of benefits compared to the commercial version of docetaxel, Taxotere(R) and this platform delivery technology can be used to improve other pharmaceuticals as well. Starpharma also applies its proprietary dendrimers to improve the performance of agrochemical products such as glyphosate (the active ingredient in Roundup(R)) and has a series of partnerships with leading industry players. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel's nationally syndicated iHeart Radio stream.
ANN: 36.52 (+0.52)
Starpharma: VivaGel(R) Condom Receives TGA Device Certification - Launch Preparations to Follow
Business Wire - Sun Jul 20, 10:05PM CDT
Starpharma (ASX:SPL) (OTCQX:SPHRY) today announced achievement of a major milestone with the receipt of Conformity Assessment Certification for the VivaGel(R) condom by the Australian Therapeutic Goods Administration (TGA). This TGA certification is similar to CE certification of devices (CE Mark) in Europe.
ANN: 36.52 (+0.52)
FDA Grants Special Protocol Assessment (SPA) Agreement for Starpharma Phase 3 Recurrent BV Trial
Business Wire - Mon Jul 14, 4:35AM CDT
Starpharma Holdings Ltd (ASX:SPL) (OTCQX:SPHRY) today announced that the US Food and Drug Administration (FDA) has granted Special Protocol Assessment (SPA) agreement on the design and planned analyses of the phase 3 clinical studies of the VivaGel(R) bacterial vaginosis (BV) product for the prevention of recurrent BV.
(0)
(0)Scroll down for more posts ▼